Neural degeneration in glaucoma involves retinal ganglion cells and neurons of their major target, the lateral geniculate nucleus (LGN). Dendrites of relay LGN neurons projecting to the visual cortex were studied by immunocytochemical and quantitative Sholl analysis in combination with confocal microscopy and 3D-morphometry. In non-human adult primate glaucoma, relay LGN neurons showed reduced dendrite complexity and length, and these changes were modified by NMDA receptor blockade. Dendrite plasticity of LGN relay neurons in adult primate glaucoma has implications for potential disease modification by treatment interventions.
Introduction
Glaucoma is a major cause of irreversible blindness worldwide, characterized by retinal ganglion cell (RGC) loss (Weinreb & Khaw, 2004) . Degeneration of retinal ganglion cells spreads trans synaptically to their main target, the lateral geniculate nucleus (LGN) of the brain in human glaucoma (Gupta, Ang, Noel de Tilly, Bidaisee, & Yucel, 2006; Gupta et al., 2009) . Previous studies in experimental primate glaucoma, show degenerative changes in the LGN including neuron loss (Weber, Chen, Hubbard, & Kaufman, 2000; Yucel, Zhang, Gupta, Kaufman, & Weinreb, 2000) , neuron atrophy (Weber et al., 2000; Yucel, Zhang, Weinreb, Kaufman, & Gupta, 2001) , reactive gliosis (Sasaoka et al., 2008) , and microglial activation (Imamura et al., 2009) . Neuron loss and atrophy increase with increasing RGC loss as do metabolic changes observed in the visual cortex in primate glaucoma. (Yucel, Zhang, Weinreb, Kaufman, & Gupta, 2003; Yucel et al., 2000 Yucel et al., , 2001 .
Dendrites are fine processes emerging from the cell body of neurons that form elaborate dendritic arbors supporting post-synaptic contact elements (Johnston & Narayanan, 2008) . Disturbances to dendrite branching can disrupt neural network organization and lead to neural dysfunction, as in human neurological disorders including Alzheimer's disease (Moolman, Vitolo, Vonsattel, & Shelanski, 2004) . Their fine structure is maintained by microtubules, and among the associated proteins, microtubule-associated protein-2 (MAP2) is enriched in dendrites (Cassimeris & Spittle, 2001; Ichihara, Kitazawa, Iguchi, Hotani, & Itoh, 2001) playing an important role in dendrite morphology and branching (Dehmelt & Halpain, 2005; Harada, Teng, Takei, Oguchi, & Hirokawa, 2002; Matus, 1994) . MAP2 has been used as a marker to assess dendrites in neurodegenerative diseases (Goedert, Crowther, & Garner, 1991; Kaufmann, Naidu, & Budden, 1995; Kwei, Jiang, & Haddad, 1993; Matesic & Lin, 1994) .
In glaucoma, dendrites in the primate retina undergo atrophy (Morgan, Uchida, & Caprioli, 2000; Weber, Kaufman, & Hubbard, 1998) . A study in which LGN interneurons confined to the LGN and relay neurons projecting to the visual cortex were not discriminated, showed dendrite changes in primate glaucoma (Gupta et al., 2007) . However, detailed dendrite evaluation of the LGN relay neurons under conditions of glaucoma at various stages of disease and following pharmacological treatment has not been previously investigated. Memantine is an NMDA glutamate open-channel blocker approved as a neuroprotective agent for the treatment of cognitive impairment in Alzheimer's disease (Reisberg et al., 2003) . The purpose of this work is to identify and quantify dendrite characteristics of LGN relay neurons in a primate model of glaucoma to determine whether they are altered, and if so, whether these changes are modifiable by memantine (Bormann, 1989 Six
LGNs from six normal adult cynomolgus monkeys (Macaca fascicularis) from the University of Wisconsin, Madison were used as controls. They were perfused intracardially with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Intraocular pressure (IOP) measurements were performed in vivo before sacrifice with a pneumatonometer (Digilab, Norwell, MA) under light sedation (intramuscular injection of 5 mg/kg of ketamine hydrochloride) and topical anesthesia (5% proparacaine hydrochloride) (Yucel et al., 2000) . The mean IOP ranged from 12.3 to 21.0 mm Hg and the maximum IOP ranged from 13.0 to 26.0 mm Hg. There was significant difference in mean IOP (P < 0.001) or maximum IOP (P < 0.001) between the vehicle-treated glaucoma group and the normal group.
Experimental glaucoma was induced in adult monkeys (Macaca fascicularis) by laser scarification of the trabecular meshwork (Hare et al., 2004) . The duration of IOP elevation was 14 months. Three animals out of 18 were excluded from the present study due to either suboptimal fixation or unidentifiable LGN layers. Two groups of monkeys were evaluated and compared: (1) seven vehicle-treated (VT) monkeys with glaucoma and (2) eight memantinetreated (MT) monkeys with glaucoma who received a daily oral dose of 4 mg/kg of memantine. In both the VT and MT glaucoma groups, the treatment was continued during 14 months until sacrifice (Hare et al., 2004) . There was no significant difference in mean IOP (P = 0.43) or maximum IOP (P = 0.73) between the VT and MT glaucoma groups (Yucel, Gupta, Zhang, Mizisin, Kalichman, & Weinreb, 2006) . Previously published optic nerve counts of these animals showed no significant difference in mean percent optic nerve fiber loss between the VT and the MT glaucoma groups .
Tissue processing
Perfusion fixation under deep general anesthesia and tissue processing and 40 lm-thick serial sections were performed (Yucel et al., 2000) . Every seventh section was mounted onto a glass slide and stained with cresyl violet. Care was taken to use the same tissue processing procedures for all monkey brains. Sections containing left LGN with six layers were randomly selected for each of the normal control animals and each of the VT and MT glaucoma animals.
Double immunofluorescence labeling of MAP2 and parvalbumin
LGN sections were double-labeled with a monoclonal antibody against MAP2 (Clone HM-2, Sigma, St. Louis, MO), and a polyclonal antibody against parvalbumin (PV28, Swant, Bellinzona, Switzerland), a calcium-binding protein, a specific marker for relay LGN neurons (Johnson & Casagrande, 1995) . The tyramide signal amplification (TSA) kit (Invitrogen Inc., ON, Canada) was used to enhance immunostaining. Sections were washed with phosphate buffered saline (1 Â PBS, 3 Â 10 min). All subsequent washes were performed with 1 Â PBS, pH 7.35 (3 Â 5 min). Sections were incubated with 0.2% Triton-X (Sigma, St. Louis, MO) in PBS (2 Â 5 min). After PBS wash, endogenous peroxidase activity was quenched by 3% H 2 O 2 (2 Â 15 min). Sections were washed with PBS and blocked in 1% blocking reagent (TSA kit 
Morphological assessment
Immunofluorescence-labeled sections were viewed using an Olympus bright field BX51 upright microscope with a color digital camera (Microfire, Optronics Inc. Goleta, CA) and a computer monitor. The LGN layers were identified as layers 1-6 from ventral to dorsal. The ventral layers 1 and 2 are magnocellular layers, while the remaining dorsal layers 3-6 are parvocellular layers. Layers 1, 4 and 6 of the left LGN are connected to the glaucomatous right eye while layers 2, 3 and 5 are connected to the non-glaucomatous left eye. We analyzed MAP2-immunoreactive dendrites of parvalbumin-positive relay neurons projecting to the primary visual cortex (Johnson & Casagrande, 1995) , located in left LGN magnocellular layer 1 and parvocellular layer 6 connected to the glaucomatous right eye.
Quantitative analysis

Confocal image acquisition
Sections from MT and VT glaucoma groups, and normal controls were examined using LaserSharp 2000 software (Biorad Cell Science Division, Hernelhempstead, UK) with a digital camera on an upright confocal laser microscope (Biorad Radiance, Bronx, NY on Nikon E800 Upright Microscope, Melville, NY) in a masked fashion.
Five sampling sites of 500 lm Â 500 lm within each magnocellular layer 1 and parvocellular layer 6 were selected. Within each sampling site, one stack of images was taken under red (CY3 for MAP2) and green (FITC for parvalbumin) channels separately with a 60Â oil-immersion objective at zoom of 1.5Â and 512 Â 512 pixels by LaserSharp2000 program. Serial stack images of 18 lm depth and 0.5 lm step size were collected using the same camera settings for power, gain, iris aperture size, and offset to maintain consistent settings for comparison. All images were obtained using a Kalman filter with three passes.
Automated tracing and 3D reconstruction
Stacks of images were imported (Neurolucida; MicroBrightField, Inc., Colchester, VT) and neurons were traced with an automated tracing software (AutoNeuron, MicroBrightField Inc., Colchester, VT). Tracing of MAP2-immunoreactive dendrites (CY3 channel) and parvalbumin-immunostained cell bodies (FITC channel) of stacks of confocal images was performed separately. Two modes of the automated tracing software were used to trace neurons: interactive mode for MAP2-immunostained dendrites, and automatic mode for parvalbumin-immunostained cell bodies. Configuration parameters used for tracing for each neuron were: (1) maximum process diameter, 1.5 lm, (2) ignore somas smaller than, 2.0 lm, (3) soma detector sensitivity, 55 and 65 for layers 1 and 6, respectively, and (4) interactive mode.
Quantitative analysis of dendrites
Immunofluorescence labeling, image acquisition and quantitative analysis of the dendrites were performed in a masked fashion. Tracings were loaded into Neurolucida software (NeuroExplorer, MicroBrightField Inc. VT, USA). A total of 45 parvalbumin-positive neurons with MAP2-immunostained dendrites were selected randomly from each magnocellular layer 1 and parvocellular layer 6 per animal for dendrite complexity analysis (Sholl analysis, NeuroExplorer) and dendrite length analysis (Branch Structure Analysis, NeuroExplorer). In Sholl analysis, once the cell body to study was selected, the intersections of dendrites and series of spheres with radii 1-14 lm, spaced at 1-lm increments, were generated by the software around the cell body. The number of dendritesphere intersections to estimate dendrite complexity was calculated by the software. The percent decrease in dendrite complexity was calculated from the difference between the average mean dendrite complexity of the normal group and mean dendrite complexity of MT and VT animals with glaucoma divided by the average mean of dendrite complexity in the normal group. Percent decrease in dendrite length was assessed in a similar manner.
Statistical analysis
The two-tailed student t-test was used to compare dendrite parameters in relay neurons in LGN layers 1 and 6 of the VT glaucoma group to the MT glaucoma group, and to the normal control group. Mean IOP, maximum IOP, and percent optic nerve fiber loss were also compared using a t-test.
Using the generalized linear models procedure of SAS statistical software (SAS Institute Inc., Cary, NC), percent decrease in dendrite complexity and dendrite length were compared between the memantine-and the vehicle-treated glaucoma groups, with mean IOP as a covariate.
Results
Dendritic plasticity in
LGN relay neurons in experimental glaucoma (Fig. 1) MAP2-immunoreactivity in magnocellular layer 1 relay neurons in normal monkey (Fig. 1A) was more intense compared to vehicletreated (VT) glaucoma monkeys (Fig. 1B) . Similar observations were made for parvocellular layer 6 (Fig. 1D and E) . MAP2-immunoreactivity in magnocellular layer 1 relay neurons in memantinetreated (MT) glaucoma monkeys (Fig. 1C) was more intense compared to VT glaucoma monkeys (Fig. 1B) . Similar observations were made for parvocellular layer 6 (Fig. 1E and F) .
Dendrite complexity (Fig. 2 ) and length were measured in normal group, VT and MT glaucoma groups (Table 1 ). In magnocellular layer 1, both mean dendrite complexity (Fig. 3A) and dendrite length (Fig. 3B) were significantly decreased in the VT glaucoma group compared with those in the normal group (11.2 ± 1.0 (Mean ± SD) vs. 23.7 ± 1.5, P < 0.0001; 18.4 ± 1.4 lm vs. 38.5 ± 3.1 lm, P < 0.0001; respectively).
In parvocellular layer 6, both mean dendrite complexity (Fig. 4A ) and length (Fig. 4B) were significantly decreased in the VT glaucoma group compared with those in the normal group (11.1 ± 1.3 vs.
21.2 ± 0.9, P < 0.0001; 16.7 ± 1.9 lm vs. 33.7 ± 2.4 lm, P < 0.0001, respectively).
Dendritic alterations in LGN relay neurons in memantine-treated glaucoma monkeys
Magnocellular layer 1
Percent decrease in dendrite complexity (Table 2) in MT glaucoma was significantly reduced compared to VT glaucoma group (38.1% ± 10.7 vs. 52.9% ± 4.2, P = 0.0047; respectively). Percent (Table 1) . MAP2 immunoreactivity in normal layer 1 (A) was more intense compared to those in the VT glaucoma (B) and MT glaucoma (C) monkeys. In layer 1, MAP2 appeared more intense in MT glaucoma (C) compared to VT glaucoma monkeys (B). Similar results were seen in parvocellular layer 6 in normal (D), VT glaucoma (E) and MT glaucoma (F) monkeys. Scale bar indicates 40 lm. decrease in dendrite length in MT glaucoma was also significantly reduced compared to VT glaucoma (Table 2) .
Parvocellular layer 6
Percent decrease in dendrite complexity (Table 2) in MT glaucoma was significantly reduced compared to VT glaucoma group (33.8% ± 6.7 vs. 47.8% ± 6.3, P = 0.0011). Percent decrease in dendrite length in MT glaucoma was also significantly reduced compared to VT glaucoma (Table 2) .
3.3. Relation with dendritic changes and mean IOP in memantinetreated and vehicle-treated glaucoma groups 3.3.1. Magnocellular Layer 1
Percent decrease in mean dendrite complexity increased with mean IOP for magnocellular layer (Fig. 5A ) for MT and VT glaucoma groups, and the linear regression of the dendrite complexity decrease on IOP was statistically significant (P < 0.05). ANCOVA test, with mean IOP as a covariate, showed significantly less percent decrease in dendrite complexity in the MT glaucoma group compared to the VT glaucoma group (P = 0.017).
The linear regression of the dendrite length decrease on IOP was statistically significant (Fig. 5B) (P < 0.05). ANCOVA test, with mean IOP as a covariate, showed significantly less percent decrease in dendrite dendrite length in the MT compared to the VT group in magnocellular layer 1 (P = 0.0032).
Percent decrease in mean dendrite complexity increased with mean IOP for parvocellular layer 6 (Fig. 6A ) for MT and VT glaucoma groups, and the linear regression of the dendrite complexity decrease on IOP was statistically significant (P < 0.05). ANCOVA test, with mean IOP as a covariate, showed significantly less percent decrease in dendrite complexity in the MT compared to the 
Table 1
Dendritic parameters of LGN relay neurons in normal monkeys, and vehicle-treated (VT) glaucoma and memantine-treated (MT) glaucoma monkeys.
Group, ID
Dendrite complexity, mean ± SD Total dendrite length (urn), mean ± SD Layer 1 Layer 6 Layer 1 Layer 6
Normal S1 22.3 ± 4.1 22.8 ± 5.7 35.1 ± 6.7 36.4 ± 9.1 S2 22.9 ± 4.9 21.6 ± 4.7 38.5 ± 8.0 31.1 ± 7.4 S4 22.7 ± 4.3 20.2 ± 3.8 37.0 ± 7.2 33.0 ± 6.9 S6
26.2 ± 6.2 20.6 ± 4.4 43.1 ± 10.7 32.7 ± 6.5 S7 23.2 ± 4.8 20.8 ± 5.6 36.2 ± 7.3 37.0 ± 9.1 S10 24.9 ± 4.7 21.3 ± 4.6 41.1 ± 8.3 32.2 ± 7.7 Mean ± SD 23.7 ± 1.5 21.2 ± 0.9 38.5 ± 3.1 33.7 ± 2.4
Vehicle-treated glaucoma 91 11.4 ± 4.7 10.9 ± 4.4 18.4 ± 6.9 16.3 ± 6.1 92 9.5 ± 3.1 9.5 ± 2.9 16.2 ± 5.8 15.0 ± 3.9 93 10.6 ± 3.2 9.4 ± 2.8 16.8 ± 5.5 13.5 ± 4.5 96 10.5 ± 4.2 10.7 ± 3.0 18.7 ± 6.2 18.1 ± 5.4 98 11.7 ± 4.5 12.4 ± 4.5 19.0 ± 7.1 18.0 ± 6.8 105 12.2 ± 5.2 11.7 ± 4.1 19.2 ± 7.2 17.4 ± 6.5 106 12.2 ± 4.6 12.8 ± 4.2 20.1 ± 7.2 18.8 ± 6.8 Mean ± SD 11.2 ± 1.0 11.1 ± 1.3 18.4 ± 1.4 16.7 ± 1.9 P value a <0.0001 <0.0001 <0.0001 <0.0001
Memantine-treated glaucoma 94 18.2 ± 6.2 14.6 ± 6.0 29.7 ± 8.5 22.6 ± 9.3 95 12.0 ± 3.3 12.6 ± 3.6 21.0 ± 6.4 18.6 ± 5.4 97 15.6 ± 6.9 14.5 ± 4.7 27.4 ± 10.2 24.5 ± 7.2 99
16.4 ± 6.3 15.2 ± 5.1 28.3 ± 9.4 24.0 ± 8.0 100 13.4 ± 3.6 12.8 ± 3.5 21.5 ± 6.4 19.0 ± 5.3 101 10.6 ± 3.7 12.5 ± 3.4 18.3 ± 6.4 19.9 ± 5.2 102 16.6 ± 7.7 16.5 ± 5.7 26.8 ± 12.5 25.7 ± 10.3 107 14.5 ± 5.7 13.6 ± 6.0 23.8 ± 9.2 20.4 ± 8.9 Mean ± SD 14.7 ± 2.5 14.0 ± 1.4 24.6 ± 4.1 21. Compared to normal group, dendrite complexity and dendrite length were reduced in VT glaucoma group. Dendrite complexity and dendrite length in MT group were significantly increased compared to VT group (P = 0.0048 and P = 0.0022, respectively). The box extends from the 25th percentile to the 75th percentile, with horizontal solid line and square at the median and mean, respectively. The bars indicate the highest and lowest values determined by the 25th and 75th percentiles. Fig. 4 . Parvocellular layer 6: Box plots for dendrite complexity (A) and dendrite length (B) in the normal group, and VT and MT glaucoma groups. Compared to normal group, dendrite complexity and dendrite length were reduced in VT glaucoma group. Dendrite complexity and dendrite length in MT glaucoma group were significantly increased compared to VT glaucoma group (P = 0.0011; P = 0.0012, respectively). The box extends from the 25th percentile to the 75th percentile, with horizontal solid line and square at the median and mean, respectively. The bars indicate the highest and lowest values determined by the 25th and 75th percentiles. VT group (P = 0.0003). The linear regression of the dendrite length decrease on IOP was statistically significant (Fig. 6B ) (P < 0.05). AN-COVA test, with mean IOP as a covariate, showed significantly less percent decrease in dendrite length in the MT compared to the VT group in parvocellular layer 6 (P = 0.0061).
Discussion
Pathologic changes in dendrites are considered an early sign of neuron injury (Bywood & Johnson, 2000) and the decrease in MAP2-immunostained dendrites is considered an early indicator of neuron injury (Kitagawa et al., 1989; Kwei et al., 1993) . Dendrites of relay LGN neurons in normal primate have been rarely studied (Wilson, 1986 (Wilson, , 1989 , and no detailed quantitative assessment of dendritic parameters are available. A previous study in experimental primate glaucoma with mild optic nerve fiber loss, showed reduction of dendritic complexity and field area in the LGN neurons without distinguishing larger relay neurons from smaller interneurons (Gupta et al., 2007) . The combination of double labeling with MAP2, a dendritic marker and parvalbumin, a cell type specific marker for relay LGN neurons (Johnson & Casagrande, 1995) , with confocal microscopy and 3D reconstruction/tracing enabled us to perform the quantitative assessment of dendrites of LGN relay neurons in glaucomatous monkeys in comparison with normal monkeys. This study shows for the first time a decrease in dendrite complexity and in length of specifically the relay LGN neurons in primate glaucoma. Furthermore, this analysis showed that both dendrite complexity and length of relay LGN neurons in glaucoma decreased with mean IOP. Further studies are needed to determine the functional significance of dendritic changes in surviving relay LGN neurons, and their involvement in visual dysfunction in glaucoma. Recent studies in retinae of primate glaucoma showed that retinal ganglion cells were less responsive, both spatially and temporally, to visual stimuli, and that the reduction in visual responsiveness most likely results from significant changes in dendritic architecture (Weber & Harman, 2005) .
Blockade of NMDA open channel receptor using memantine attenuated decrease in dendrite complexity and in length in relay LGN neurons in primate glaucoma. Confirmation of these results by ANCOVA analysis using mean IOP as covariate, suggests that the difference between memantine-treated and vehicle-treated groups is not due to differences in mean IOP between groups. Memantine also protected cell body size in the LGN in glaucoma and this may be in part due to action on NMDA receptors in relay LGN neurons (Jones, Tighilet, Tran, & Huntsman, 1998) . Memantine may also be acting on the NMDA receptor subtype located in the retina (Grunert, Haverkamp, Fletcher, & Wassle, 2002) and the visual cortex (Huntley et al., 1994) , each major sources of excitatory input to the LGN (Montero & Wenthold, 1989 ). Although the expression of NMDAR1 receptor subunit, part of all NMDARs, is increased in LGN layer in primate glaucoma (Yucel, Darabie, Wang, Kaufman, & Gupta, 2006) , the expression of other NMDAR subunits (Liu et al., 2007) and the cellular location of NMDARs (synaptic or extrasynaptic) (Hardingham, Fukunaga, & Bading, 2002; Sattler, Xiong, Lu, MacDonald, & Tymianski, 2000) that are implicated in controlling their effect on neuronal viability, are not yet known in normal and glaucomatous LGN. This knowledge may be important to understand the effect of memantine of relay neurons in glaucomatous LGN since memantine has been shown to act preferentially on the extrasynaptic NMDA receptors (Leveille et al., 2008) . It is not clear whether the extent of dendritic changes following memantine treatment contributes the decrease in amplitude reduction of visually-evoked cortical potential in memantine-treated glaucoma monkeys (Hare et al., 2004) . Memantine failed to demonstrate a neuroprotective treatment effect on visual fields of glaucoma patients in a large clinical trial. Nonetheless, the finding of measurable dendrite plasticity in central visual neurons following administration of memantine suggests that targeting LGN neurons in glaucoma is a strategy worth exploring to prevent visual dysfunction in glaucoma. 
